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Abstract 
Mastectomy is effective treatment for ductal carcinoma in situ (DCIS) but some women will develop chest wall 
recurrence. Most chest wall recurrences that develop after mastectomy are invasive cancer and are associated with 
poorer prognosis. Past studies have been unable to identify factors predictive of chest wall recurrence. Therefore, it 
remains unclear if a subset exists of women with DCIS treated by mastectomy experience a high rate of recurrence 
in whom more aggressive treatment may be of benefit. We report outcomes of all women in Ontario (N = 1,546) 
diagnosed with pure DCIS from 1994 to 2003 treated with mastectomy without radiotherapy and evaluate factors 
associated with the development of chest wall recurrence. Treatments and outcomes were validated by chart review. 
Proportional differences were compared using Chi square analyses. Survival analyses were used to study the devel‑
opment of chest wall recurrence in relation to patient and tumor characteristics. Median follow‑up was 10.1 years. 
Median age was 57.1 years. 36 patients (2.3%) developed chest wall recurrence. The 10‑year actuarial chest wall 
recurrence‑free survival rates and invasive chest wall recurrence‑free survival rates were 97.6 and 98.6%, respectively. 
There was no difference in cumulative 10 year rates of chest wall recurrence by age at diagnosis (<40 years = 5.2%, 
40–44 years = 1.3%, 45–50 years = 2.9%, >50 years = 2.1%; p = 0.19), nuclear grade (high = 3.0%, intermedi‑
ate = 1.4%, low = 1.0%, unreported = 2.5%; p = 0.41), or among women with close or positive resection margins 
(positive = 3.0%, 2 mm or less = 1.4%, >2 mm = 1.5%, unreported = 2.8%; p = 0.51). On univariate and multivariable 
analysis, none of the factors were significantly associated with the development of chest wall recurrence. In this popu‑
lation cohort, individuals treated by mastectomy experienced low rates of chest wall recurrence. We did not identify a 
subset of patients with a high rate of chest wall recurrence, including those with positive margins.
Keywords: Breast cancer, DCIS, Mastectomy, Radiotherapy, Surgery, Carcinoma in situ
© 2015 Klein et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Ductal carcinoma in  situ (DCIS), a non-invasive breast 
cancer, comprises about 25% of mammographically-
detected breast cancers (Ernster et al. 2002). About one-
third of patients diagnosed with DCIS are treated by 
mastectomy. Women will receive mastectomy as treat-
ment for DCIS in cases where the disease is extensively 
involving the breast such that complete excision using 
breast-conserving surgery is not feasible or due to patient 
preference (Katz et al. 2005; Rakovitch et al. 2007; Chin-
Lenn et  al. 2013). Past studies report that individuals 
treated by mastectomy for DCIS experience low rates 
of chest wall recurrence (1–5% at 10  years) but some 
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women will develop recurrent disease involving the chest 
wall (Carlson et al. 2007; Owen et al. 2013; Chadha et al. 
2012; Fitzsullivan et al. 2013; Meijnen et al. 2008).
Women who develop a chest wall recurrence after mas-
tectomy for DCIS have a poorer prognosis compared to 
those who do not develop chest wall recurrence (Owen 
et al. 2013; Chadha et al. 2012; Lee et al. 2006; Godat et al. 
2009; Rashtian et al. 2008). As a result, several investiga-
tors have attempted to identify factors predictive of chest 
wall recurrence after mastectomy for DCIS, in an effort 
to identify individuals who may benefit from post-mas-
tectomy chest wall radiotherapy, but results are incon-
sistent. Specifically, some studies report that women with 
close or involved resection margins after mastectomy 
have an increased risk of chest wall recurrence while oth-
ers have not identified an increased risk of recurrence 
(Carlson et al. 2007; Owen et al. 2013; Godat et al. 2009; 
Chan et al. 2011; Childs et al. 2013).
Past studies are limited in their ability to evaluate fac-
tors associated with an increased risk of chest wall recur-
rence due to the inclusion of few patients often from a 
single institution (which may not be representative of the 
outcomes of a population of women with DCIS), inclu-
sion of cases treated by either breast-conserving surgery 
or mastectomy or short follow-up intervals with subse-
quent few events and limited statistical power (Carlson 
et al. 2007; Owen et al. 2013; Chadha et al. 2012; Fitzsul-
livan et  al. 2013; Meijnen et  al. 2008; Godat et  al. 2009; 
Rashtian et al. 2008; Chan et al. 2011; Childs et al. 2013; 
Kelley et  al. 2011; Silverstein et  al. 1995; Spiegel and 
Butler 2003; Vargas et  al. 2005). As a result, it remains 
unclear if a subset of individuals with DCIS treated by 
mastectomy, including those with close or positive resec-
tion margins, has an increased risk of chest wall recur-
rence such that post-mastectomy radiotherapy might be 
of benefit. We report the outcomes of a large population 
cohort of women diagnosed with pure DCIS from 1994 
to 2003 treated by mastectomy with median follow-up 
of 10  years. Our objective is to evaluate factors associ-
ated with the risk of chest wall recurrence after treatment 




The method of identification of individuals in the DCIS 
population cohort was previously described (Rakovitch 
et al. 2013). In summary, we obtained full text electronic 
copies of all breast pathology reports held at the Ontario 
Cancer Registry (OCR) from January, 1994 through 
December, 2003. These reports included diagnoses of 
DCIS, represented by International Classification of Dis-
eases (ICD) code 233, invasive breast cancer (ICD 174), 
or benign conditions. Patient identifiers were removed 
and each case received a study ID. An automated data 
extraction algorithm abstracted pathology data from 
these reports (Currie et  al. 2006). We received approxi-
mately 1,50,000 breast pathology reports. All patient 
identifiers were removed from the reports to ensure 
patient confidentiality. Cases with a final diagnosis of 
invasive cancer, benign disease, or DCIS with microin-
vasion were excluded, as were patients diagnosed with 
invasive breast cancer within 6  months of diagnosis of 
DCIS. We linked these cases with the OCR database to 
exclude patients with previous history of invasive cancer.
To determine each patient’s surgical treatment, we 
linked the study database to the Canadian Institute for 
Health Information (CIHI) database of hospital discharge 
summaries and the Ontario Health Insurance Plan data-
base of physician billings. Surgical treatment was vali-
dated by reviewing the operative report in the primary 
chart. Cases treated by breast conserving surgery (with 
or without radiation) were excluded. The date of diagno-
sis is the date of the initial breast cancer surgery associ-
ated with pathological diagnosis of DCIS. We determined 
the number of breast surgical procedures (benign or 
malignant) performed by each surgeon annually through 
the study period using CIHI and ranked surgical volume 
into quintiles (lowest to highest).
Pathology
For the current study of cases treated by mastectomy, all 
pathology reports were manually reviewed to confirm 
the diagnosis of pure DCIS and to obtain data on resec-
tion margin status and width. The following data were 
abstracted from original pathology reports: nuclear grade 
(low, intermediate, high, unreported), comedo necrosis 
(present, absent), multifocality (present, absent). Resec-
tion margin width was coded as ≤2 mm if DCIS was at 
or within 2  mm from the margin, >2  mm if the closest 
distance from tumor to the inked resection margin was 
more than 2 mm or unreported if the closest margin was 
not reported. Comedo necrosis and multifocality were 
coded as absent if not indicated in the pathology report. 
Tumor size was not reported for >20% of cases and there-
fore was not included in the analysis.
Outcomes
We identified cases that developed chest wall recurrence 
after mastectomy by searching the CIHI database for 
surgical procedures (e.g. excisional biopsy) performed 
on the ipsilateral chest wall at least 6  months following 
mastectomy. Individuals who developed recurrent dis-
ease within 6 months of their initial DCIS diagnosis were 
excluded (N = 30). We identified the histological diagno-
sis (benign, DCIS or invasive cancer) of the recurrence 
Page 3 of 9Klein et al. SpringerPlus  (2015) 4:335 
by reviewing the corresponding pathology report or 
through linkage with the Ontario Cancer Registry and 
CIHI in cases where the pathology report was not avail-
able. All outcomes were determined from the date of 
DCIS diagnosis. Ipsilateral chest wall (invasive or DCIS) 
and contralateral breast recurrence are defined by the 
detection of invasive cancer or DCIS that developed in 
the ipsilateral chest wall or opposite breast, respectively, 
6 months or more beyond the initial diagnosis of DCIS. 
The last date of follow-up is March 31, 2010. Individu-
als were censored at the time of their initial recurrence. 
Overall mortality is estimated from the date of diagno-
sis of DCIS to the date of death from any cause. The date 
of death was determined from the Registered Persons 
Database and cause of death from the OCR. To adjust 
for co-morbid illnesses we identified all diagnoses during 
the 12 months prior to that of DCIS as recorded in CIHI 
using Deyo’s method (Dunne et al. 2009).
Statistical analyses
We studied the development of a chest wall recurrence 
(DCIS or invasive) as a first event in relation to patient 
characteristics, tumor characteristics and treatment. 
Cumulative incidence estimates were used to illustrate 
the probability of breast cancer death over time while 
accounting for the competing risk of other (non-breast 
cancer) cause of death (Dunne et al. 2009). Univariate and 
multivariable analyses were performed to examine the 
effect of each covariate using Cox proportional hazards 
model. The hazard ratios resulting from this semi-par-
ametric approach were used as measures of association 
between each risk factor and the outcomes. In subgroup 
analyses, non-parametric Kaplan–Meier method was 
used to estimate the survival times of groups and log 
rank test was used to test for equality between groups. 
In accordance with institutional policy, to avoid the risk 
of identity disclosure and risk patient confidentiality we 
were unable to report cell size for cell counts between 1 
and 5. Cell counts between 1 and 5 are reported as ≤5.
Results
We identified 5,322 women diagnosed with pure DCIS 
treated from 1994 to 2003; of these, 1,821 were treated 
with mastectomy. Patients were excluded if they received 
post-mastectomy radiation (N  =  163), had evidence of 
lymph node metastases (N = 82) at the time of diagno-
sis, developed invasive breast cancer within 6 months of 
diagnosis (N = 30) or change in diagnosis after pathology 
review (N  =  22) because our objective was to evaluate 
the outcomes of individuals with pure DCIS treated by 
mastectomy alone. The study population includes 1,524 
individuals. The mean age was 57.1  years. 426 patients 
(28.0%) had high grade DCIS, 668 (43.8%) had margins 
≤2  mm, 436 individuals (28.6%) had negative resection 
margins >2  mm, and 340 (22.3%) patients had multifo-
cal DCIS. Most women (96%) had no co morbidities 
(Table 1).
After mean follow-up of 10.2 years, 36 patients (2.4%) 
developed chest wall recurrence (17 were DCIS, 19 were 
invasive cancer). The 5- and 10-year actuarial rates of 
any chest wall recurrence-free survival were 98.4 and 
97.5%. The 5- and 10-year actuarial DCIS recurrence-free 
survival rates were 99.2 and 98.9%, and invasive chest 
wall recurrence-free survival rates were 99.2 and 98.6% 
respectively. The 10-year contralateral breast cancer-free 
survival rate was 94.0%. The 10  year breast-cancer spe-
cific survival rate was 95.9% and the 10-year overall sur-
vival rate was 86.5%.
Individuals who developed an invasive chest wall recur-
rence had a significantly higher risk of dying of breast 
cancer compared to those who did not develop an inva-
sive recurrence. At 10 years, the cumulative rate of breast 
Table 1 Patient characteristics
N number of patients, SD standard deviation
N = 1524
Age










≤2 mm 668 (43.8%)
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cancer mortality was 40.3% for patients who developed 
invasive recurrence, 23.5% for individuals who developed 
recurrent DCIS and 3.6% for those who had no recur-
rence (Gray test p < 0.0001).
We examined the features of women who developed 
chest wall recurrence in an effort to identify factors 
associated with an increased risk of chest wall recur-
rence following mastectomy for pure DCIS. Individuals 
who developed chest wall recurrence were more likely 
to be younger than 45 years at diagnosis (19.4 vs. 16.2%; 
p = 0.20), have high nuclear grade DCIS (36.1 vs. 27.8%; 
p  =  0.41), or close resection margins (52.8 vs. 43.6%; 
p = 0.23) but these differences did not achieve statistical 
significance (Table 2).
On univariate (and multivariable) analysis, none of 
the factors including resection margin width (univariate 
HR: ≤2  mm =  2.1 (95% CI 0.86–5.1), p =  0.10), age at 
diagnosis (age < 45 years, HR = 1.29 (95% CI 0.55–3.02); 
p = 0.72), high nuclear grade (univariate HR = 3.0 (95% 
CI 0.4–23.1), p = 0.29), subtype, presence of multifocal-
ity (univariate HR =  0.7 (95% CI 0.28–1.62), p =  0.36), 
presence of comedo necrosis (univariate HR = 1.7 (95% 
CI 0.23–13.1), p = 0.60) or breast surgeon volume (uni-
variate HR for low volume  =  2.6 (95% CI 0.89–7.37), 
p = 0.08) were associated with an increased risk of chest 
wall recurrence (Table 3).
We evaluated the 10  year actuarial rates of chest wall 
recurrence among subsets of individuals with adverse 
features of DCIS. We did not observe an increased rate 
of chest wall recurrence among individuals with close 
(≤2  mm) resection margins, young age at diagnosis or 
high nuclear grade. The 10-year actuarial rate of chest 
wall recurrence was 2.7% (19/668) for those with margins 
≤2 mm and 2.1% (7/436) for those with wider (>2 mm) 
negative margins (p  =  0.24). The Kaplan–Meier curve 
illustrating actuarial chest wall recurrence-free survival 
in subgroups divided by margin status is shown in Fig-
ure  1; no difference was seen between the groups with 
close (≤2 mm), negative (>2 mm) or unreported surgical 
margins (p = 0.44). Furthermore, the 10 year rate of chest 
Table 2 Patient characteristics and  chest wall recurrence 
following mastectomy for DCIS
N number of patients, SD standard deviation
Chest Wall Recurrence
Variable No (N = 1488) Yes (N = 36) p value
Age
Mean (SD) 57.2 (12.1) 54.1 (11.3) 0.13
<45 241 (16.2%) 7 (19.4%) 0.20
45–50 236 (15.9%) 7 (19.4%)
>50 1011 (67.9%) 22 (61.1%)
Nuclear Grade
Low 98 (6.6%) <5 0.41
Intermediate 282 (19.0%) <5
High 413 (27.8%) 13 (36.1%)
Unreported 695 (46.7%) 18 (50.0%)
Resection Margin Width
≤2 mm 649 (43.6%) 19 (52.8%) 0.23
>2 mm 429 (28.8%) 7 (19.4%)
Unknown 410 (27.6%) 10 (27.8%)
Multifocality
Absent/Unreported 1154 (77.6%) 30 (83.3%) 0.41
Present 340 (22.4%) 6 (16.7%)
Necrosis
Present 604 (40.6%) 14 (38.9%) 0.74
Absent/unreported 884 (59.4%) 22 (61.1%)
Histologic Subtype
Solid 806 (54.2%) 27 (75.0%) 0.07
Cribriform 252 (16.9%) <5
Other 107 (7.2 %) <5
Unreported 323 (21.7%) <5
Node Dissection
Yes 574 (38.6%) 11 (30.6%) 0.33
No 914 (61.4%) 25 (69.4%)
Table 3 Predictors of  chest wall recurrence after  mastec-
tomy for DCIS: Univariate analysis
CI confidence interval, HR hazard ratio




Age Continuous ‑ 0.98 (0.95‑1.01) 0.19
<45 >50 1.29 (0.55‑3.02) 0.72
45‑50 >50 1.3 (0.58‑3.16) 0.7
Nuclear Grade High Low 3.0 (0.4‑23.1) 0.29
Intermediate Low 1.4 (0.16‑12.60) 0.76
Unreported Low 2.3 (0.31‑17.53) 0.41
Margin Width ≤2 mm >2 mm 2.1 (0.86‑5.1) 0.10
Unreported 1.59 (0.54, 4.37) 0.35
Multifocality Present Absent 0.7 (0.28‑1.62) 0.36
Necrosis Present Absent 1.7 (0.23‑13.1) 0.60
Histological 
Subtype
Cribriform Solid 0.5 (0.17‑1.37) 0.16
Other Solid 0 0.98




1 5 2.6 (0.89‑7.37) 0.08
2 5 1.1 (0.31‑3.70) 0.91
3 5 1.80 (0.59‑5.49) 0.30
4 5 1.4 (0.43‑4.26) 0.61
Year of Diag‑
nosis
1997‑1999 1994‑1996 0.60 (0.28‑1.29) 0.13
2000‑2002 1994‑1996 0.43 (0.19‑1.00) 0.13
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wall recurrence was 1.4% among women with margins 
≤1 mm, and 1% for those with positive resection margins 
(p = 0.33).
Among women younger than 45 years at diagnosis, the 
10-year actuarial rate of chest wall recurrence was 2.7% 
(7/248), 2.9% (7/243) for those aged 45–50  years com-
pared to 2.4% (22/1033) for those older than 50  years 
(p = 0.2). The 10-year actuarial rate of chest wall recur-
rence was 3.5% (13/426) among women with high grade 
DCIS, ≤5% (≤5/286) for those with intermediate grade 
DCIS, 2.5% (18/713) for those with unreported grade 
and ≤5% (≤5/99) for those with low grade disease 
(p = 0.44). We then evaluated the outcomes of those with 
several adverse features. Among 130 women younger 
than 45  years at diagnosis with close resection margins 
(≤ 2 mm), the 10-year actuarial rate of chest wall recur-
rence was < 5%. Among 83 women younger than 45 years 
with high grade DCIS, the 10 year actuarial rate of chest 
wall recurrence was <5%. Among 202 women with high 
grade DCIS and margins ≤2  mm, the 10  year actuarial 
rate of chest wall recurrence was 3.2% (Table 4).
Discussion
It is well documented that factors such as young age at 
diagnosis, presence of high grade DCIS and close or posi-
tive resection margins are associated with an increased 
risk of local (in-breast) recurrence following breast-
conserving therapy for DCIS, but it remains unclear if 
women with these features experience an increased risk 
of chest wall recurrence after mastectomy (Bijker et  al. 
2001; Dunne et al. 2009; Van Zee et al. 1999; Vicini et al. 
2000; Tunon-de-Lara et al. 2001). We evaluated the long-
term rates of chest wall recurrence in a large population 
cohort of women with pure DCIS treated by mastectomy 
alone (without radiotherapy). The cumulative 10  year 
rate of chest wall recurrence was 2.4%. We did not find a 
significant increased risk of chest wall recurrence associ-
ated with resection margin status, nuclear grade or age at 
diagnosis.
Past studies, summarized in Table  5, corroborate our 
findings of low rates of chest wall recurrence after mas-
tectomy for pure DCIS (Carlson et al. 2007; Owen et al. 
2013; Chadha et  al. 2012; Fitzsullivan et  al. 2013; Mei-
jnen et  al. 2008; Godat et  al. 2009; Rashtian et  al. 2008; 
Chan et  al. 2011; Childs et  al. 2013; Kelley et  al. 2011; 
Silverstein et  al. 1995; Spiegel and Butler 2003; Vargas 
et al. 2005) but the reported impact of close or positive 
resection margins on the risk of chest wall recurrence 
is less consistent. Chadha et al. (2012) reported the out-
comes of 214 women with DCIS treated by mastectomy 
with median follow-up of 4.6  years; 2 of 24 (8%) cases 
with margins ≤1  mm developed chest wall recurrence 
compared to none of 187 women with wider resection 
margins (p = 0.013). Another study including 80 women 
with DCIS treated by mastectomy with resection margins 
<10  mm with median follow-up period of 82.3  months, 
reported that 5 of 31 women (16%) with margins ≤2 mm 
developed chest wall recurrence compared to 1 of 49 
(2%) with wider margins (p  =  0.04). However, data 
derived from these studies are limited by the inclusion of 
Figure 1 Kaplan–Meier curve showing chest wall recurrence‑free survival in women with pure DCIS treated with mastectomy divided into sub‑
groups by resection margin status. Blue close (≤2 mm) margins, Red negative (>2 mm) margins, Green unreported margin status.
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small numbers of patients from a single institution with 
few chest wall recurrences and short follow-up intervals 
(Carlson et  al. 2007; Chadha et  al. 2012; Rashtian et  al. 
2008).
A larger single institutional study of 803 patients with 
median follow-up of 6.3  years found an increased risk 
of chest wall recurrence (5.0%) among 59 women with 
margins ≤1  mm compared to a rate of 3.6% among 35 
women with margins 1.1–2.9  mm and 1% among 744 
women with wider negative resection margins (≥3 mm) 
(p = 0.005) (Fitzsullivan et al. 2013). Another population-
based study included 637 women with DCIS treated by 
mastectomy with median follow-up interval of 12  years 
(Owen et  al. 2013). The authors reported a 6.2% rate 
of chest wall recurrence among 31 women with posi-
tive margins compared to 3.6% for those (N =  35) with 
close (≤2  mm) margins and 1.5% for those with wider 
negative margins, but the differences were not statisti-
cally significant. In our population, the 10  year rates of 
chest wall recurrence were 2.7% among 668 women with 
close margins ≤2  mm, 1.4% among women with nega-
tive margins ≤1  mm, 1% among women with positive 
resection margins and 2% for 436 women with margins 
>2 mm (p = 0.33). Overall, the data do not suggest that 
the presence of close or positive resection margins after 
mastectomy is associated with a significant risk of chest 
wall recurrence such that routine chest wall radiotherapy 
is warranted.
Table 4 Chest wall recurrence rates by patient subgroup
Variable N Chest wall recurrences 10 year actuarial chest wall recurrence rate p value
Age 0.20
<45 248 7 2.7
45–50 243 7 2.9
>50 1033 22 2.4
Nuclear Grade 0.44
Low 99 <5 <5%
Intermediate 286 <5 <5%
High 426 13 3.5
Unreported 713 18 2.6
Margin Width 0.24
≤2 mm 668 19 2.7
>2 mm 436 7 2.1
Missing 367 10 2.9
Multifocality 0.37
Present 340 6 2.7
Absent 1184 30 1.9
Necrosis 0.80
Present 618 14 2.5
Absent 906 27 1.3
Histologic Subtype 0.08
Solid 833 27 3.6
Cribriform 256 <5 <5
Other 107 <5 <5
Unreported 328 <5 <5
Year of Diagnosis
1994–1996 378 15 4.0 0.1
1997–1999 499 12 2.4
2000–2002 647 9 1.4
Combined factors
Age <45 years + high grade
grgrade
83 <5 <5
Age < 45 years + margins <2 mm 130 <5 <5
High grade + margins <2 mm 202 6 3.2
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We did not find an increased risk of chest wall recur-
rence among individuals with high grade DCIS. Past 
studies report rates of chest wall recurrence among indi-
viduals with high grade DCIS treated by mastectomy 
range from 1.5 to 6.4% at 5–10 years (Owen et al. 2013; 
Fitzsullivan et al. 2013; Chan et al. 2011). Rashtian et al. 
reported a higher rate of chest wall recurrence among 
16 patients with high grade DCIS and margins ≤2  mm 
(25%) compared to 3% for 64 patients without either risk 
factor (p = 0.0055) after median follow-up of 61 months.
(12) In our population cohort, the 10 year rates of chest 
wall recurrence was 3.0% among 426 patients with high 
grade disease, and <5% among 286 with intermediate 
grade DCIS and <5% for 99 cases with low grade DCIS 
(p =  0.44). Among 202 women with high grade disease 
and close (≤2  mm) negative margins 6 developed chest 
wall recurrence corresponding to a 10-year actuarial 
recurrence risk of 3.2%.
Some studies report an increased risk of chest wall 
recurrence among young women with DCIS treated 
by mastectomy (Owen et  al. 2013). In one study of 55 
women younger than 40  years at diagnosis the 10  year 
rate of chest wall recurrence was 7.5% compared to 1.5% 
for older women (p  =  0.003). Overall, published stud-
ies report 10 year rates of chest wall recurrence ranging 
from 0 to 7.5% at 5–10 years among younger women with 
DCIS treated by mastectomy (Carlson et al. 2007; Owen 
et  al. 2013; Chan et  al. 2011; Childs et  al. 2013). Our 
population cohort included 248 women age <45 years at 
diagnosis; the 10-year rate of chest wall recurrence was 
2.7% similar to the rate of 3% for those 45–50 years and 
2.4% for women older than 50 years (p = 0.20). Among 
130 women <45  years at diagnosis with close (≤2  mm) 
margins, the 10  year rate of chest wall recurrence was 
<5%. For 83 women <45 years with high grade DCIS, the 
10  year rate of chest wall recurrence was <5%. Overall, 
we did not find a higher risk of recurrence in younger 
women. Further data on the outcomes of younger women 
are needed to determine if younger women have an 
increased risk of chest wall recurrence.
The strength of this study is that it reports the out-
comes of a large population-based cohort of women with 
DCIS treated by mastectomy with long-term follow-up 
(median 10.2  years). Individuals who developed chest 
wall recurrence without a surgical excision or biopsy for 
tissue confirmation of the chest wall recurrence would 
not have been identified; therefore, the cumulative rate 
of chest wall recurrence (with or without simultane-
ous distant metastases) may be underestimated. Chest 
wall radiotherapy is associated with a risk of acute and 
late toxicity, including a detrimental effect on cosmesis 
following breast reconstruction. Therefore, we aimed 
to identify baseline factors associated with the develop-
ment of isolated chest wall recurrence in women with 
pure DCIS treated by mastectomy, in an effort to identify 
the subset of individuals who might benefit from post-
mastectomy adjuvant radiotherapy. We did not identify 
any feature, alone or in combination, that was associated 
with a significant increased risk of chest wall recurrence 
(at 10 years of follow-up) such that routine radiotherapy 
should be recommended. However, several pathology 
reports did not contain information on all pathological 
Table 5 Studies reporting the impact of close or positive resection margins on chest wall recurrence after mastectomy 
for DCIS
CWR chest wall recurrence, m months, N number of patients, NR not reported, NS not statistically significant, y years
All Patients in Study Close or Positive Margins
Study
(Author, Year)
Median follow-up N CWR rate Margin definition N CWR rate p value
Current 10.1 y 1546 2.3% Positive 305 3.0% 0.24
≤2 mm 220 1.4% 0.84
Childs, 2013 [14] 7.6 y 142 1.4% positive 21 4.8%
≤2 mm 23 4.3%
Owen, 2013 [6] 12 y 637 1.9% Positive 31 6.2% NS
<2 mm 35 3.6% NS
Fitzsullivan, 2013 [8] 6.3 y 803 1% <1 mm 59 5.0% <0.001
Chadha, 2012 [7] 4.6 y 211 0.9% <1 mm 24 8.3% 0.013
Chan, 2011 [13] 8 y 193 NR Positive 4 0
Godat, 2009 [11] 4.5 y 83 1.1% <2 mm 20 0
Rashtian, 2008 [12] 61 m 80 7.5% <2 mm 31 16.1% 0.036
Carlson, 2007 [5] 82.3 m 223 5.1% <1 mm 19 10.5% 0.32
Spiegel, 2003 [17] 10.5 y 44 0 <1 mm 6 0 NS
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features. Lack of completeness in pathological reporting 
of DCIS has been previously described (Rakovitch et al. 
2004; Staradub et  al. 2002). Improved adherence will 
facilitate the impact of pathological features on risks of 
recurrence.
Conclusions
Individuals with pure DCIS treated by mastectomy expe-
rience low rates of chest wall recurrence. We did not 
identify a subset of patients, including those with close or 
positive resection margins, who experienced a high rate 
of chest wall recurrence.
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